Skip to main content

Table 3 Univariate analyses comparing factors associated with continuation or withdrawal of treatment with mirogabalin

From: Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study

VariablesContinued treatment
(n= 163)
Withdrew from treatment
(n= 24)
pvalue
Age (years)71.8 ± 12.7 (30–94)75.0 ± 9.9 (49–91)0.23a
Sex, female/male110/5319/50.25b
Diagnosis  0.98b
 LCS11817
 CSM285
 LDH91
 CTS81
 Others10
BMI (kg/m2)22.9 ± 4.1 (18–33)23.2 ± 3.9 (19–31)0.78a
DM1520.89b
Adverse events with pregabalin   
 Somnolence92 (56.4%)5 (20.8%)0.0017b
 Dizziness39 (23.9%)11 (45.8%)0.015b
 Edema4 (2.5%)3 (12.5%)0.012b
 Weight gain3 (1.8%)0 (0%)0.51b
 Others2 (1.2%)2 (8.3%) 
Lack of efficacy with pregabalin27 (16.6%)5 (20.8%)0.61b
NeP score (points)7.0 ± 1.7 (6–12)6.9 ± 1.7 (6–12)0.80b
Primary dose of mirogabalin (mg)3.1 ± 1.2 (5–10)3.3 ± 1.8 (5–10)0.52b
Adverse events with mirogabalin   
 Somnolence44 (27%)6 (25%)0.84b
 Dizziness16 (9.8%)7 (29.2%)0.0069b
 Edema7 (4.3%)4 (16.7%)0.016b
 Epigastric pain0 (0%)2 (8.3%)< 0.0001b
 Weight gain1 (0.6%)0 (0%)0.70b
 Fatigue1 (0.6%)0 (0%)0.70b
  1. Data are expressed as the mean ± standard deviation (range) or n (%).
  2. LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM diabetes mellitus, NeP neuropathic pain
  3. a Student’s t-test
  4. b Chi-squared test